Immunome, Inc. (IMNM)
$5.35
-0.02 (-0.37%)
Rating:
Recommendation:
-
| Symbol | IMNM |
|---|---|
| Price | $5.35 |
| Beta | 0.833 |
| Volume Avg. | 0.08M |
| Market Cap | 64.889M |
| Shares () | - |
| 52 Week Range | 2.09-8.97 |
| 1y Target Est | - |
| DCF Unlevered | IMNM DCF -> | |
|---|---|---|
| DCF Levered | IMNM LDCF -> | |
| ROE | -106.05% | Strong Sell |
| ROA | -121.00% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 32.33% | Neutral |
| P/E | - | |
| P/B | 2.81 | Strong Buy |
Latest IMNM news
About
Download (Excel)Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.